What Is Oncology Competitive Intelligence? A Guide for Biopharma Teams
Oncology moves faster than almost any other therapeutic field. New mechanisms, combination regimens and biomarker-defined subgroups appear every month, and a single data readout can reshape a treatment algorithm overnight. Oncology competitive intelligence (CI) is the discipline of collecting, interpreting and distributing information about that moving landscape so that teams can make better decisions.
Competitive intelligence is analysis, not just information
A news alert tells you that a Phase 3 trial read out. Intelligence tells you what the result means for your asset, which patients it affects, how it compares with the current standard of care, and what the likely competitor response will be. The difference is context and implication, and that is where experienced scientific analysts add the most value.
What oncology CI typically covers
- Pipeline tracking: assets in development, their phase, mechanism, indication and sponsor.
- Clinical trial intelligence: design, endpoints, enrollment criteria, timelines and readouts.
- Conference coverage: what was presented at meetings such as ASCO, ESMO, ASH and SABCS, and why it matters.
- Regulatory and market access signals: approvals, label changes, guideline updates and reimbursement decisions.
- Treatment algorithms and benchmarking: how therapies are sequenced and how products compare head to head.
Who uses it
Oncology CI is not owned by one function. Commercial teams use it for launch planning and positioning. Medical affairs teams use it to prepare for scientific exchange and to brief medical science liaisons. R&D and clinical development teams use it to refine trial design and anticipate enrollment competition. Business development teams use it to evaluate licensing and acquisition targets.
Why a cancer-area-by-cancer-area approach works
Oncology is not one disease. The biology, endpoints and standards of care in non-small cell lung cancer look nothing like those in chronic lymphocytic leukemia. Strong CI programs build deep expertise one cancer area at a time, so analysts recognize which data are truly practice-changing and which are incremental.
Building a program that works
- Start with decisions. List the decisions your teams must make in the next 12 months, then work backward to the intelligence each one needs.
- Prioritize cancer areas and competitors. Covering everything dilutes quality. Be explicit about what is in and out of scope.
- Standardize the format. Concise summaries with a clear “implications” section are read; long data dumps are not.
- Set a cadence. Combine continuous surveillance, event-driven coverage around conferences, and periodic deep-dive landscapes.
- Close the loop. Ask stakeholders which intelligence changed a decision, and refine from there.
Build, buy or blend
Many organizations pair a small internal CI team with an external specialist partner. Internal staff own strategy and stakeholder relationships; the partner supplies scientific depth and capacity across many cancer areas, especially during peak conference periods.
Want to see what a mature oncology CI program looks like in practice? Request information and we will share sample deliverables.
Keep reading: oncology conference coverage at ASCO, ESMO and ASH, oncology pipeline tracking and oncology treatment algorithm maps.